Features of Appel et al for Low-Risk Pediatric Lymphocyte-Predominant Hodgkin's Lymphoma (LPHL) That Requires Minimal Therapy

Description

Appel et al identified pediatric patients with low-risk lymphocyte-predominant Hodgkin's lymphoma (LPHL) who can be managed with minimal therapy. This can avoid late toxicities from chemotherapy or radiation. The authors are from multiple hospitals and universities in the United States and Canada.

Features of a patient with Hodgkin's disease who can undergo minimal treatment:

(1) age < 22 years

(2) lymphocyte predominant Hodgkin's disease (LPHL)

(3) stage IA or IIA

(4) absence of B symptoms

(5) absence of bulky disease (nodal aggregate > 6 cm in diameter, mediastinal mass greater than one third of the thoracic diameter)

Status at Diagnosis	Initial Therapy	Less Than Complete Response
single lymph node	resection	AV-PC with or without IFRT
other	3 cycles AV-PC chemotherapy	IFRT

where:

• AV-PC is doxorubicin (Adriamycin), vincristine, prednisone and cyclophosphamide

• IFRT is involved field radiation therapy.

To read more or access our algorithms and calculators, please log in or register.

Features of Appel et al for Low-Risk Pediatric Lymphocyte-Predominant Hodgkin's Lymphoma (LPHL) That Requires Minimal Therapy

Description

Specialty